Ovid Therapeutics Inc. Company Profile

01:15 EST 15th November 2018 | BioPortfolio

Ovid Therapeutics Inc. is a privately-held, New York based, biopharmaceutical company committed to transforming the lives of patients with rare and orphan diseases of the brain and few, if any, treatment options - patients who currently have no hope of cure or improvement. Ovid focuses on patients and their needs. Using the significant operational, product development and business development experience of its management team, Ovid aims to become a leading neurology company, with multiple products and a rich pipeline coupled with compelling research and development.

News Articles [793 Associated News Articles listed on BioPortfolio]

Ovid Therapeutics (OVID) Presents At Baird's Global Healthcare Conference - Slideshow

Ovid Therapeutics (OVID) Presents At Jefferies 2018 Global Healthcare Conference - Slideshow

Ovid Therapeutics Drug, Invented 41 Years Ago, May Help People With A Rare Disorder

This morning, Ovid Therapeutics, a small biotechnology company, is announcing data indicating that a drug, gaboxadol, may be of some help for patients with a condition called Angelman Syndrome.

Ovid Therapeutics starts ELEKTRA and ARCADE trials for rare epilepsies

Ovid Therapeutics has commenced two Phase ll ELEKTRA and ARCADE trials of OV935/TAK-935 for the treatment of paediatric patients with...Read More... The post Ovid Therapeutics starts ELEKTRA and ARCAD...

Ovid Therapeutics Presents Additional Data and Analyses from the Phase 2 STARS Clinical Trial with OV101

Ovid Therapeutics (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced additional explorator...

Recent Research Analysts' Ratings Updates for Ovid Therapeutics

They set a "buy" rating and a $20.00 price target on the stock. 5/10/2018 - Ovid Therapeutics was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "strong sell" rating.

Positive Results For Ovid Drug, But Questions Remain

This morning, Ovid Therapeutics, a small biotechnology company, is announcing data indicating that a drug, gaboxadol, may be of some help for patients with a condition called Angelman Syndrome.

Ovid’s Angelman Syndrome Therapy Hits Prespecified Endpoint Phase II Trial, Shares Drop Significa...

Ovid Therapeutics is shouting good news from the rooftops regarding its mid-stage Angelman Syndrome study, but investors are not convinced.

PubMed Articles [493 Associated PubMed Articles listed on BioPortfolio]

Design and implementation of a tool for conversion of search strategies between PubMed and Ovid MEDLINE.

Both PubMed and Ovid MEDLINE contain records from the MEDLINE database. However, there are subtle differences in content, functionality, and search syntax between the two. There are many instances in ...

RNA Therapeutics (Almost) Comes of Age: Targeting, Delivery and Endosomal Escape.

RNA-targeted therapeutics for lipid disorders.

To summarize recent developments in the field of RNA-directed therapeutics targeting lipid disorders that are not effectively managed.

A Review of Therapeutics in Clinical Development for Respiratory Syncytial Virus and Influenza in Children.

Respiratory syncytial virus (RSV) and influenza are important viral pathogens worldwide. Children, in particular, bear considerable burdens of morbidity and mortality associated with these viruses. Th...

Community-based interventions for prevention of Type 2 diabetes in low- and middle-income countries: a systematic review.

Type 2 diabetes is an increasing burden in low- and middle-income countries (LMICs). Knowledge of effective prevention programs in LMICs is thus important. The aim of this review was to establish an o...

Clinical Trials [164 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1274 Associated Companies listed on BioPortfolio]

Ovid Therapeutics Inc.

Ovid Therapeutics Inc. is a privately-held, New York based, biopharmaceutical company committed to transforming the lives of patients with rare and orphan diseases of the brain an...

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

Vaxiion Therapeutics, Inc.

Vaxiion is dedicated to the design and development of intelligent drug-delivery technologies with special emphasis on targeted oncology therapeutics. Vaxiion Therapeutics was spun...

ProVation Medical/Wolters Kluwer Health

ProVation® Medical is part of Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals and institutions in medicine, nursi...

More Information about "Ovid Therapeutics Inc." on BioPortfolio

We have published hundreds of Ovid Therapeutics Inc. news stories on BioPortfolio along with dozens of Ovid Therapeutics Inc. Clinical Trials and PubMed Articles about Ovid Therapeutics Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Ovid Therapeutics Inc. Companies in our database. You can also find out about relevant Ovid Therapeutics Inc. Drugs and Medications on this site too.

Quick Search


Relevant Topics

Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Alzheimer's Disease
Of all the types of Dementia, Alzheimer's disease is the most common, affecting around 465,000 people in the UK. Neurons in the brain die, becuase  'plaques' and 'tangles' (mis-folded proteins) form in the brain. People with Al...

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...

Corporate Database Quicklinks

Searches Linking to this Company Record